Mineralys Therapeutics (NASDAQ:MLYS) Hits New 12-Month Low on Analyst Downgrade
Mineralys Therapeutics (NASDAQ:MLYS) Hits New 12-Month Low on Analyst Downgrade
Mineralys Therapeutics, Inc. (NASDAQ:MLYS – Get Rating) reached a new 52-week low on Friday after Credit Suisse Group lowered their price target on the stock from $40.00 to $38.00. Credit Suisse Group currently has an outperform rating on the stock. Mineralys Therapeutics traded as low as $15.04 and last traded at $15.20, with a volume of 25683 shares traded. The stock had previously closed at $15.38.
在瑞信集團將股票的目標價格從 $40.00 降至 38.00 美元之後，Mineralys 治療公司（NASDAQ：MLYS — 獲得評級）在周五達到 52 週新低。瑞士信貸集團目前的股票表現優於評級。米納利藥物治療低至 15.04 美元，最後交易價格為 15.20 美元，交易量為 25683 股。該股票之前已收盤 15.38 美元。
Several other research firms also recently weighed in on MLYS. Guggenheim began coverage on Mineralys Therapeutics in a research report on Tuesday, March 7th. They set a "buy" rating and a $32.00 target price on the stock. Wells Fargo & Company initiated coverage on Mineralys Therapeutics in a report on Tuesday, March 7th. They issued an "overweight" rating and a $27.00 price objective on the stock. Evercore ISI assumed coverage on Mineralys Therapeutics in a report on Tuesday, March 7th. They issued an "outperform" rating on the stock. Stifel Nicolaus began coverage on Mineralys Therapeutics in a research note on Tuesday, March 7th. They issued a "buy" rating and a $45.00 target price for the company. Finally, Bank of America began coverage on Mineralys Therapeutics in a research note on Tuesday, March 7th. They set a "buy" rating and a $39.00 price objective for the company. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of "Buy" and an average target price of $36.20.
其他幾家研究公司最近也稱重 MLYS。古根海姆開始覆蓋礦物質治療藥物在週二的研究報告, 3 月 7 日.他們設定了「買入」評級和 32.00 美元的股票目標價格。富國銀行 & 公司在週二的報告中啟動了 Mineralys 治療藥物的報導, 3 月 7 日.他們對股票發出了「超重」評級和 27.00 美元的價格目標。永可 ISI 承擔了礦物藥物治療在週二的報告覆蓋, 3 月 7 日.他們對股票發出了「跑贏大市」評級。斯蒂菲爾尼古拉斯開始覆蓋礦物質治療藥物在研究筆記上週二, 3 月 7 日.他們為該公司發布了「買入」評級和 45.00 美元的目標價格。最後, 美國銀行開始覆蓋 Mineralys 治療藥物在週二的研究筆記, 3 月 7 日.他們為該公司設定了「購買」評級和 39.00 美元的價格目標。六位研究分析師將該股票評級為買入評級，根據 MarketBeat.com 的數據，該股票的共識評級為「買入」，平均目標價為 36.20 美元。
Insider Buying and Selling at Mineralys Therapeutics
內幕購買和銷售礦物治療
In other news, Director Ra Capital Management, L.P. purchased 1,250,000 shares of the stock in a transaction dated Tuesday, February 14th. The shares were bought at an average cost of $16.00 per share, for a total transaction of $20,000,000.00. Following the transaction, the director now owns 1,867,229 shares in the company, valued at $29,875,664. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other news, Director Ra Capital Management, L.P. purchased 1,250,000 shares of the stock in a transaction dated Tuesday, February 14th. The shares were bought at an average cost of $16.00 per share, for a total transaction of $20,000,000.00. Following the transaction, the director now owns 1,867,229 shares in the company, valued at $29,875,664. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Adam Scott Levy bought 6,250 shares of the firm's stock in a transaction that occurred on Tuesday, February 14th. The stock was bought at an average price of $16.00 per share, for a total transaction of $100,000.00. Following the completion of the acquisition, the chief financial officer now directly owns 350,811 shares in the company, valued at $5,612,976. The disclosure for this purchase can be found here. Insiders have acquired 1,568,750 shares of company stock valued at $25,100,000 in the last quarter.
在其他消息, 主任鐳資本管理, L.P. 購買了 1,250,000 股股份的交易日期星期二, 2 月 14 日.這些股票以每股 16.00 美元的平均成本買入，總交易額為 20 萬美元。交易完成後，董事現在擁有該公司的 1,867,229 股股份，價值為 29,875,664 美元。該交易在向美國證券交易委員會提交的文件中披露，該文件可在以下位置獲得： 證券交易所網站。在其他消息, 主任鐳資本管理, L.P. 購買了 1,250,000 股股份的交易日期星期二, 2 月 14 日.這些股票以每股 16.00 美元的平均成本買入，總交易額為 20 萬美元。交易完成後，董事現在擁有該公司的 1,867,229 股股份，價值為 29,875,664 美元。該交易在向美國證券交易委員會提交的文件中披露，該文件可在以下位置獲得： 證券交易所網站。此外，首席財務官亞當·斯科特·利維買了 6,250 股在星期二發生的交易中，2 月 14 日。該股票以每股 16.00 美元的平均價格買入，總交易額為 10 萬美元。收購完成後，首席財務官現在直接擁有該公司的 350,811 股股份，價值 5,612,976 元。可以找到此次購買的披露 這裡。內部人士在上個季度收購了 1,568,750 股價值 25 億美元的公司股份。
Mineralys Therapeutics Stock Performance
礦物療法股票表現
About Mineralys Therapeutics
關於礦物療法
(Get Rating)
(取得評分)
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. Mineralys Therapeutics Inc is based in RADNOR, Pa.
Mineralys Theraptics Inc 是一家臨床階段的生物製藥公司，專注於開發針對異常升高醛固酮驅動的疾病的藥物。礦物療法公司總部位於賓夕法尼亞州 RANOR。
See Also
另請參閱
- Get a free copy of the StockNews.com research report on Mineralys Therapeutics (MLYS)
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don't Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
- Europe Raises Interest Rates, Should the Fed Follow?
- 獲取有關礦物療法研究報告的免費副本
- 這種具有巨大增長前景的小技術正接近買點
- 不要追逐聯邦快遞更高，等待回調
- 3 個防禦性技術投資組合的股票
- 牛奶這些 3 現金奶牛的股息
- 歐洲提高利率，美聯儲應該跟隨嗎？
Receive News & Ratings for Mineralys Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mineralys Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
每日接收礦物質藥物治療的新聞和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收 Mineralys 治療和相關公司的最新新聞和分析師評級的簡要每日摘要。
譯文內容由第三人軟體翻譯。